HK Stock Market Move | Joinn Laboratories (06127) opened more than 4% higher, and is expected to achieve a year-on-year increase in net profit attributable to the mother of approximately 2.14 to 3.71 times in 2025.

Joinn Laboratories (06127) opened high by more than 4%, as of the time of writing, it rose 4.42% to 26 Hong Kong dollars with a trading volume of 1.4092 million Hong Kong dollars. On the news front, on January 20, Joinn Laboratories announced that it expects to achieve operating income of approximately RMB 1.573 billion to RMB 1.738 billion by 2025, a decrease of approximately RMB 0.28 billion to RMB 0.446 billion compared to the same period last year, representing a decrease of about 13.9% to 22.1% year-on-year. It is expected to achieve a net profit attributable to the company's shareholders of approximately RMB 0.233 billion to RMB 0.349 billion by 2025, an increase of approximately RMB 1.59 billion to RMB 2.75 billion compared to the same period last year, representing an increase of about 214.0% to 371.0% year-on-year. It is expected to achieve a net profit attributable to the company's shareholders excluding non-recurring gains and losses of approximately RMB 0.246 billion to RMB 0.37 billion by 2025, an increase of approximately RMB 2.23 billion to RMB 3.46 billion compared to the same period last year, representing an increase of about 945.2% to 1,467.7% year-on-year. Among them: the net profit contributed by the fair value changes of biological assets is approximately RMB 0.452 billion to RMB 0.5 billion. The net profit of laboratory services and other businesses is approximately RMB -0.206 billion to RMB -1.3 billion. During the reporting period, the increase in market prices of biological assets combined with their natural growth value added, driving the fair value of assets positively contributed to the company's performance. During the reporting period, the company's laboratories continued to maintain a good and stable operational status, but due to the lag effects of intense competition in the industry in previous periods, the revenue and gross profit margin of the contracts fulfilled during the reporting period decreased year-on-year, leading to a decrease in profit contribution from laboratory services business.